Modern Approaches in Cancer Pharmacology

  • Sukriti Goyal
  • Abhinav GroverEmail author


Cancer, known by many names including Carcinoma, Malignancy, Neoplasms and Tumor is the leading cause of death worldwide. Depending on the anatomical part of human body, Cancer can be named as lung cancer, pancreatic cancer, breast cancer etc. Owing to the present lifestyle, the burden of leading cause of death in economically developed countries is expected to rise. Several factors including environmental, smoking or tobacco, consumption of alcohol, dietary routine, radiation and infections have a profound impact on most cancers than hereditary factors. Evidently, although hereditary factors cannot be altered, lifestyle and environmental factors can be modified which might be a step towards prevention of cancer. Modern treatment methods of cancer include a multimodal approach rather than replacing the conventional treatment methods completely. This chapter will provide an input of various treatment methods employed to combat cancer and the modern approaches being considered to counter the various problems associated with cancer.



AG is thankful to Jawaharlal Nehru University for usage of all computational facilities. AG is grateful to University Grants Commission, India for the Faculty Recharge Position. SG acknowledges the Young Scientist Fellowship from Department of Health Research (DHR), New Delhi.

Competing Interests

The authors declare that they have no competing interests.


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMedGoogle Scholar
  2. 2.
    Ames BN, Gold LS, Willett WC (1995) The causes and prevention of cancer. Proc Natl Acad Sci 92:5258–5265CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Michalas SP (2000) The Pap test: George N. Papanicolaou (1883–1962): a screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 90:135–138CrossRefPubMedGoogle Scholar
  4. 4.
    Tabar L, Gad A, Holmberg L, Ljungquist U, Group KCP et al (1985) Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 325:829–832CrossRefGoogle Scholar
  5. 5.
    Whipple AO (1950) Radical surgery in the treatment of cancer. Ann Surg 131:812CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Keevil G (1896) The Roentgen rays. Br Med J 1:433CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wolf GT, Hong WK, Fisher SG, Urba S, Endicott JW et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690CrossRefPubMedGoogle Scholar
  8. 8.
    Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26(5 Suppl 14):66–73PubMedGoogle Scholar
  11. 11.
    Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(1 Suppl 3):13–19CrossRefPubMedGoogle Scholar
  12. 12.
    Sawyers C (2004) Targeted cancer therapy. Nature 432:294–297CrossRefPubMedGoogle Scholar
  13. 13.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMedGoogle Scholar
  14. 14.
    Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828CrossRefPubMedGoogle Scholar
  15. 15.
    Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4:97–105CrossRefPubMedGoogle Scholar
  16. 16.
    Fraley ME, Arrington KL, Bilodeau MT, Hartman GD, Hoffman WF, et al (2004) Tyrosine kinase inhibitors. Google PatentsGoogle Scholar
  17. 17.
    Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971–979CrossRefPubMedGoogle Scholar
  18. 18.
    Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123CrossRefPubMedGoogle Scholar
  19. 19.
    Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMedGoogle Scholar
  20. 20.
    Wang HF, Feng B, Sun Y, Tang GB, Min J et al (2013) Proteasome inhibitor Brotezomib induces apoptosis of colon cancer cells SW480 through inhibiting PI3K/Akt pathway. Prog Mod Biomed 11:013Google Scholar
  21. 21.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–30CrossRefPubMedGoogle Scholar
  22. 22.
    Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364CrossRefPubMedGoogle Scholar
  23. 23.
    Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ et al (2003) A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357–371CrossRefPubMedGoogle Scholar
  25. 25.
    Lu L, Payvandi F, Wu L, Zhang L-H, Hariri RJ et al (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78–86CrossRefPubMedGoogle Scholar
  26. 26.
    Frei E, Freireich EJ, Gehan E, Pinkel D, Holland JF et al (1961) Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood 18:431–454Google Scholar
  27. 27.
    Wood AJ, Gorlick R, Goker E, Trippett T, Waltham M et al (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041–1048CrossRefGoogle Scholar
  28. 28.
    Goyal S, Jamal S, Shanker A, Grover A (2015) Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. BMC Genomics 16:S8CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M et al (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14:7519–7525CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Nie S (2010) Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 5:523–528CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659CrossRefPubMedGoogle Scholar
  32. 32.
    Jackson SE, Chester JD (2015) Personalised cancer medicine. Int J Cancer 137:262–266CrossRefPubMedGoogle Scholar
  33. 33.
    Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683CrossRefPubMedGoogle Scholar
  34. 34.
    Tobinick EL (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 22:119–125CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.School of Biotechnology, Jawaharlal Nehru UniversityNew DelhiIndia
  2. 2.Department of Bioscience and BiotechnologyBanasthali UniversityTonkIndia

Personalised recommendations